02.04.2012 - Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
02 Apr 2012
02.04.2012 Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
© Shionogi B.V. 2020. All rights reserved. This website is owned by Shionogi B.V. Registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180. Registered address is Kingsfordweg 151, 1043GR, Amsterdam, the Netherlands.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi Limited is not responsible for its contents.